Study Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of anti-CD5 CART cells in patients with relapsed and/or refractory T cell lymphoma or leukemia.
Want to learn more about this trial?
Request More InfoInterventions
anti-CD5 CAR T cellsDRUG
anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Peking University Shenzhen Hospital | Shenzhen | Guangdong | China |